Indications of PET/CT in oncology

Transcription

1 Monday, August 27, 2012 Session 1, 10:00-10:40 Indications of PET/CT in oncology Helle Westergren Hendel MD, PhD, assistant professor Bacelor in Leadership & Health Ecomomics Head of Clinical PET, Herlev Hospital Department of Clinical Physiology & Nuclear Medicine, PET & cyclotron Institute of Diagnostic Science University of Copenhagen Denmark

2 Case study of a famous American 18F FDG-PET and beyond Diffusion-weighted imaging (DWI) Dynamic contrast-enhanced MRI Perfusion CT Blood oxygenation level dependent MRI (BOLD-MRI) MR spectroscopy (MRS) Structural imaging Functional imaging

3 Why functional imaging? The lesion was suspected by FDG-PET in January With current PET systems the limit of resolution is cm which translates into a tumor size of g or cells Cancers are usually not diagnosed until they reach a size of g, or cells The lesion was visible on CT in April

4 Learning point Metabolic changes precede structural changes

5 History of FDG-PET Glucose transporter 2-deoxy-D-Glucose 2-deoxy-D-glucose was developed as a chemotherapeutic agent hexokinase 2-deoxy-D Glucose-6-phosphate Lazlo J et al. Effects of glucose analogues (2-deoxy-D-glucose, 2-deoxy-D-galactose) on experimental tumors J Natl Cancer Inst 1960;24: Metabolic trapping TCA cyclus Oxidativ phosphylat ion Cancer cell

6 Metabolic trapping 2-deoxy-D-glucose 18F-FDG 18F-FDG 6 phosphate

7 History of FDG-PET Glucose transporter 2-deoxy-D-Glucose 2-deoxy-D-glucose was developed as a chemotherapeutic agent hexokinase 2-deoxy-D Glucose-6-phosphate Lazlo J et al. Effects of glucose analogues (2-deoxy-D-glucose, 2-deoxy-D-galactose) on experimental tumors J Natl Cancer Inst 1960;24: Metabolic trapping TCA cyclus Oxidativ phosphylat ion Cancer cell

8 History of FDG-PET 1976 & 1977 Glucose transporter 18F-FDG F-FDG was developed to study cerebral glucose metabolism based on PET Brookhaven National Laboratories hexokinase 1977 First PET brain imaging studies UCLA 18F-FDG-6-phosphate Metabolic trapping TCA cyclus Oxidativ phosphylat ion Warburg effect in a cancer cell

9 Biologic Current characteristics and future research of tracer Isotopes 18F 11C 13N 15O 64Cu 68Ga Others

10 PET/CT in Western Europe 2010 Providers: mobile centres 64% public facilities PET/CT 87%

11 Indications Outline for FDG-PET Diagnosis and screening Staging (re-staging) Recurrence Treatment monitoring Treatment planning

12 The normal FDG-PET Physiological high uptake in the brain In the heart (variable) Excretion into urine bladder The liver has inhomogenous moderately high uptake Spleen is just visible (less activity than liver)

13 Indications An abnormal for FDG-PET P998, S0

14 An abnormal FDG-PET 2 years later (after operation) Thyroid cancer P998, S0

15 An abnormal FDG-PET 2 years later (after operation) P998, S0 Breast cancer

16 An abnormal FDG-PET 2 years later Pitt fall P998, S0 Diverticulosis - colonoscopy P998, S0

17 An abnormal FDG-PET 2 years later Hodgkin s lymphoma P998, S0

18 Learning point Learning point Thyroid cancer Breast cancer FDG is an unspecific all round tracer Diverticulosis Hodgkin P998, S0

19 Diagnosis and screening Unknown primary SPN Unknown cancer 2-5% disease - economy radiation exposure - ethics

20 Screening Unknown with primary PET Unknown primary Known secondary (metastases) Lymph node (neck) Liver metastases Lung metastases Primary is identified in app 20% of the cases

21 Screening Single pulmonary with PET nodule Highly suspicious of malignancy

22 Single pulmonary nodule

23 Single pulmonary nodule FDG-negative tumor 111In-octreotide positive carcinoid Sensitivity 80%

24 Unknown cancer?

25 Unknown cancer?

26 Unknown cancer?

27 Unknown cancer?

28 Unknown cancer?

29 Indications FDG-PET Diagnosis and screening Staging (re-staging) Recurrence Treatment monitoring Treatment planning

30 TNM Staging T = tumor N = node Sentinel node M = metastase Example: T2N3M1

31 Staging TNM Staging 17 y male. Two months of common cold and pain in left ear. Now bleeding from the nose Cancer of the rhinopharynx MRI has assessed the tumor to be in operable

32 T-stage T Staging Tumor in rhinopharynx

33 N-stage N Staging Lymph nodes on both sides of the neck

34 M-stadium M Staging Metastases anteriorly in L4 Metastases in illiac bone

35 Learning point point Total body examination has same radiation exposure to the patient as regional examination Same tracer used for primary and secondaries in different organ systems

36 Indications for FDG-PET Diagnosis and screening Staging (re-staging) Recurrence Treatment monitoring Treatment planning

37 Colo-rectal cancer. Increased CEA

38 Colo-rectal Lung metastases cancer. Increased CEA

39 Liver metastasis

40 Recurrence Colo-rectal cancer. Increased CEA The metastasis in the liver and the left lung were resected. Check-up scanning two years later

41 Colo-rectal cancer. Increased CEA Recurrence in the rectum (stapler line)

42 Collective review : The Emerging Role of 18 F- Fluorodeoxyglucose Positron Emission Tomography in the Management of Primary and Recurrent Rectal Cancer Presented in part at the Colon and Rectal Surgery Specialty Session, American College of Surgeons 90 th Annual Clinical Congress, New Orleans, LA, October David B. Chessin MD, Ravi P. Kiran MD, Timothy Akhurst MD and Jose G. Guillem

43 Colo-rectal cancer. Increased CEA Benign uptake due to operation The former lung metastases

44 First scan: Liver and lung metastasis Second scan: Local recurrence

45 Learning point PET has high sensitivity and specificity in many common cancers incl metastasis and relapse

46 Indications for FDG-PET Diagnosis and screening Staging (re-staging) Recurrence Treatment monitoring Treatment planning

47 Treatment monitoring 76 y male, large celle B cell lymphoma

48 Before After

49 Før Before Before After After

50 Learning point Morphologic lesions can be FDG- positive or FDG-negative

51 PET in early response evaluation CT kan ikke forudse om Behandlingen hjælper

52 Learning point Change in FDG-metabolism can predict treatment response/survival

53 Indications for FDG-PET Diagnosis and screening Staging (re-staging) Recurrence Treatment monitoring Treatment planning

54 Treatment planning 74 y male with lung cancer. RTP

55 Change of GTV actelasis necrosis tumor

56 Indications for FDG-PET Diagnosis and screening Staging (re-staging) Recurrence Treatment monitoring Treatment planning

57 Indications Other tracers for than FDG-PET Prostate cancer Bone PET Hypoxia

58 Other tracers than FDG Prostate cancer 99mTc HDP planar bone scan

59 Lipid synthesis prostate cancer [ 11 C] Acetate Acetate Acetate AcetylCoA synthetase (mithochondria) Acetyl CoA TCA Fatty Acid Synthase Malonyl CoA TCA cyclus Oxidativ phosphylation Fatty Acids (phosphatidylcholin) CO 2 Acetate is activated to acetyl-coa which is oxidized to CO 2 and H 2 O in normal cells

60 18F choline/acetate Axial-fused PET/CT images demonstrate pathological 18F-choline uptake (a) in the prostate (b) in three pelvic lymph nodes (c) in bones

61 Bone metabolism [ 18 F]NaF 18F NaF is chemisorbed onto bone surface by exchanging with OHgroups in hydroxapatite crystal of bone to form fluoroapatite. Same uptake mechanism as 99mTc-MDP TCA cyclus Oxidativ phosphylation

62 99mTc MDP bone scan vs 18FNaF PET Examination time: 3-4 h min

63 Oxygenation treatment resistance [ 18 F]MISO Nitroreductase Re-oxidation TCA cyclus Oxidativ phosphylation Hypoxia is a key factor in Tumour aggression/progression Resistance to therapy Independent negative predictive factor

64 F-MISO in radiotherapy The 18FDG-PET image: Increased uptake in both the oropharyngeal tumour (arrow) and in the left neck nodal metastasis (asterix). The 18F- MISO images The left neck nodal metastasis is shown to be hypoxic Dose escalation map superimposed on CT with Planning Target Volume (red). Isodose lines show conformality to hypoxic lymph node with a maximum dose increase by 20%.

65 Neuroendocrine cell - tagets tumors for functional imaging 111In Octreotid 123I MIBG 68Ga Octreotid High affinity (SSTR2) Generator product Simple labelling L-Tyrosine 18F-DOPA 11C-HTP* *hyrdoxy trhptophan L-DOPA Dopamine Norepinephrine NET GLUT Epinephrine Loss of NET or VMAT in tumor cell dedifferentiation 18F-FDG 18F DOPA

66